The cardiogenomics testing panels market size has grown rapidly in recent years. It will grow from $1.55 billion in 2025 to $1.75 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to rising prevalence of cardiovascular diseases, limited access to genetic testing, increasing awareness of inherited cardiac disorders, adoption of conventional cardiovascular diagnostic techniques, high cost of early sequencing technologies.
The cardiogenomics testing panels market size is expected to see rapid growth in the next few years. It will grow to $2.78 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to advancements in next-generation sequencing (NGS), integration of ai and bioinformatics in diagnostics, government initiatives supporting precision medicine, growing adoption of multi-gene and whole exome panels, increasing demand for personalized cardiovascular care. Major trends in the forecast period include personalized genetic risk profiling, ai-driven diagnostic tools, tele-cardiology and remote monitoring, integration of multi-gene panels, advanced bioinformatics platforms.
The rising prevalence of inherited cardiovascular diseases is expected to drive growth in the cardiogenomics testing panels market. Inherited cardiovascular diseases (ICDs) include heart and blood vessel disorders passed down genetically from parents to offspring. Advances in genetic testing and diagnostics have contributed to an increase in diagnosed cases by enabling more precise detection of previously unidentified conditions. Cardiogenomics testing panels assist in inherited cardiovascular diseases by analyzing genetic mutations responsible for hereditary heart disorders, facilitating early diagnosis, risk evaluation, and personalized treatment plans. For example, in February 2025, the Joint Strategic Needs Assessment, a UK community health center, reported that Blackpool recorded 185 cardiovascular disease deaths in 2023 compared to 178 in 2022. This growing prevalence is fueling expansion in the cardiogenomics testing panels market.
The rising healthcare expenditure is anticipated to drive the expansion of the cardiogenomics testing panels market in the coming years. Healthcare expenditure encompasses the total resources, including funds spent by governments, private entities, and individuals, on providing, maintaining, and enhancing health services and medical care. The increase in healthcare spending is primarily attributed to the growing prevalence of chronic diseases that demand long-term treatment, continuous monitoring, and specialized medical interventions. This expenditure supports cardiogenomics testing panels by financing advanced genetic analyses that allow for the early detection and prevention of inherited cardiovascular diseases, thereby improving patient outcomes and lowering long-term costs. For example, in May 2024, the Office for National Statistics, a UK government department, reported that total healthcare expenditure rose by 5.6% in nominal terms in 2023, marking a 0.9% growth compared to 2022. Consequently, the rising healthcare expenditure fuels the growth of the cardiogenomics testing panels market.
In May 2025, GeneDx Inc., a US-based genetic testing company, completed the acquisition of Fabric Genomics Inc. for an undisclosed sum. Through this acquisition, GeneDx intends to enhance its genomic interpretation capabilities by incorporating Fabric Genomics’ AI-powered variant interpretation platform, boosting scalability and diagnostic insights across its testing services. Fabric Genomics, Inc., a US-based genomics and bioinformatics firm, focuses on cardiogenomics testing panels and clinical genetic variant interpretation.
Major companies operating in the cardiogenomics testing panels market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Illumina Inc., Actia Group, Invitae Corporation, Fulgent Genetics Inc., GeneDx Inc., Ambry Genetics Corporation, Helix OpCo Inc., Centogene Gmbh, Blueprint Genetics Inc., Strand Life Sciences Pvt. Ltd., Genes2Me Pvt. Ltd., BioAro Inc., GENinCode Plc, Igenomix S.L., Asper Biotech Ltd.
North America was the largest region in the cardiogenomics testing panels market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiogenomics testing panels market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiogenomics testing panels market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the cardiogenomics testing panels market by increasing the cost of importing sequencing instruments, reagents, and consumables, particularly impacting regions such as North America, Europe, and Asia-Pacific where most advanced equipment is sourced from specialized suppliers. The resulting cost increase has slowed adoption in smaller diagnostic labs, while larger hospitals and academic institutes have mitigated the effect through local sourcing or partnerships. Positive impacts include incentivizing domestic manufacturing of certain testing kits and consumables, potentially reducing future dependency on imports and lowering costs over time.
The cardiogenomics testing panels market research report is one of a series of new reports that provides cardiogenomics testing panels market statistics, including cardiogenomics testing panels industry global market size, regional shares, competitors with a cardiogenomics testing panels market share, detailed cardiogenomics testing panels market segments, market trends and opportunities, and any further data you may need to thrive in the cardiogenomics testing panels industry. This cardiogenomics testing panels market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cardiogenomics testing panels are genetic tests that examine multiple genes to determine inherited risks for cardiovascular diseases, including cardiomyopathies, arrhythmias, and familial hypercholesterolemia. They support early diagnosis, personalized treatment, and assessment of family risk.
The primary product types of cardiogenomics testing panels are single-gene panels, multi-gene panels, and whole exome sequencing panels. Single-gene panels test a specific gene to detect mutations or variants linked to a particular inherited condition or disease. The technologies employed include next-generation sequencing, PCR-based testing, microarrays, and others. These panels are applied in areas such as inherited cardiovascular diseases, arrhythmias, cardiomyopathies, congenital heart diseases, and others, and are used by hospitals and clinics, diagnostic laboratories, academic and research institutions, and other end users.
The cardiogenomics testing panels market consists of revenues earned by entities by providing services such as genetic risk assessment, early diagnosis, and personalized treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiogenomics testing panels market also includes sales of comprehensive cardiomyopathy panels, cardiac arrhythmia panels, and direct-to-consumer genomic profiles. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cardiogenomics testing panels market size is expected to see rapid growth in the next few years. It will grow to $2.78 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to advancements in next-generation sequencing (NGS), integration of ai and bioinformatics in diagnostics, government initiatives supporting precision medicine, growing adoption of multi-gene and whole exome panels, increasing demand for personalized cardiovascular care. Major trends in the forecast period include personalized genetic risk profiling, ai-driven diagnostic tools, tele-cardiology and remote monitoring, integration of multi-gene panels, advanced bioinformatics platforms.
The rising prevalence of inherited cardiovascular diseases is expected to drive growth in the cardiogenomics testing panels market. Inherited cardiovascular diseases (ICDs) include heart and blood vessel disorders passed down genetically from parents to offspring. Advances in genetic testing and diagnostics have contributed to an increase in diagnosed cases by enabling more precise detection of previously unidentified conditions. Cardiogenomics testing panels assist in inherited cardiovascular diseases by analyzing genetic mutations responsible for hereditary heart disorders, facilitating early diagnosis, risk evaluation, and personalized treatment plans. For example, in February 2025, the Joint Strategic Needs Assessment, a UK community health center, reported that Blackpool recorded 185 cardiovascular disease deaths in 2023 compared to 178 in 2022. This growing prevalence is fueling expansion in the cardiogenomics testing panels market.
The rising healthcare expenditure is anticipated to drive the expansion of the cardiogenomics testing panels market in the coming years. Healthcare expenditure encompasses the total resources, including funds spent by governments, private entities, and individuals, on providing, maintaining, and enhancing health services and medical care. The increase in healthcare spending is primarily attributed to the growing prevalence of chronic diseases that demand long-term treatment, continuous monitoring, and specialized medical interventions. This expenditure supports cardiogenomics testing panels by financing advanced genetic analyses that allow for the early detection and prevention of inherited cardiovascular diseases, thereby improving patient outcomes and lowering long-term costs. For example, in May 2024, the Office for National Statistics, a UK government department, reported that total healthcare expenditure rose by 5.6% in nominal terms in 2023, marking a 0.9% growth compared to 2022. Consequently, the rising healthcare expenditure fuels the growth of the cardiogenomics testing panels market.
In May 2025, GeneDx Inc., a US-based genetic testing company, completed the acquisition of Fabric Genomics Inc. for an undisclosed sum. Through this acquisition, GeneDx intends to enhance its genomic interpretation capabilities by incorporating Fabric Genomics’ AI-powered variant interpretation platform, boosting scalability and diagnostic insights across its testing services. Fabric Genomics, Inc., a US-based genomics and bioinformatics firm, focuses on cardiogenomics testing panels and clinical genetic variant interpretation.
Major companies operating in the cardiogenomics testing panels market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Illumina Inc., Actia Group, Invitae Corporation, Fulgent Genetics Inc., GeneDx Inc., Ambry Genetics Corporation, Helix OpCo Inc., Centogene Gmbh, Blueprint Genetics Inc., Strand Life Sciences Pvt. Ltd., Genes2Me Pvt. Ltd., BioAro Inc., GENinCode Plc, Igenomix S.L., Asper Biotech Ltd.
North America was the largest region in the cardiogenomics testing panels market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiogenomics testing panels market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiogenomics testing panels market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the cardiogenomics testing panels market by increasing the cost of importing sequencing instruments, reagents, and consumables, particularly impacting regions such as North America, Europe, and Asia-Pacific where most advanced equipment is sourced from specialized suppliers. The resulting cost increase has slowed adoption in smaller diagnostic labs, while larger hospitals and academic institutes have mitigated the effect through local sourcing or partnerships. Positive impacts include incentivizing domestic manufacturing of certain testing kits and consumables, potentially reducing future dependency on imports and lowering costs over time.
The cardiogenomics testing panels market research report is one of a series of new reports that provides cardiogenomics testing panels market statistics, including cardiogenomics testing panels industry global market size, regional shares, competitors with a cardiogenomics testing panels market share, detailed cardiogenomics testing panels market segments, market trends and opportunities, and any further data you may need to thrive in the cardiogenomics testing panels industry. This cardiogenomics testing panels market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cardiogenomics testing panels are genetic tests that examine multiple genes to determine inherited risks for cardiovascular diseases, including cardiomyopathies, arrhythmias, and familial hypercholesterolemia. They support early diagnosis, personalized treatment, and assessment of family risk.
The primary product types of cardiogenomics testing panels are single-gene panels, multi-gene panels, and whole exome sequencing panels. Single-gene panels test a specific gene to detect mutations or variants linked to a particular inherited condition or disease. The technologies employed include next-generation sequencing, PCR-based testing, microarrays, and others. These panels are applied in areas such as inherited cardiovascular diseases, arrhythmias, cardiomyopathies, congenital heart diseases, and others, and are used by hospitals and clinics, diagnostic laboratories, academic and research institutions, and other end users.
The cardiogenomics testing panels market consists of revenues earned by entities by providing services such as genetic risk assessment, early diagnosis, and personalized treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiogenomics testing panels market also includes sales of comprehensive cardiomyopathy panels, cardiac arrhythmia panels, and direct-to-consumer genomic profiles. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cardiogenomics Testing Panels Market Characteristics
3. Cardiogenomics Testing Panels Market Supply Chain Analysis
4. Global Cardiogenomics Testing Panels Market Trends and Strategies
5. Cardiogenomics Testing Panels Market Analysis of End Use Industries
7. Global Cardiogenomics Testing Panels Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cardiogenomics Testing Panels Total Addressable Market (TAM) Analysis for the Market
9. Cardiogenomics Testing Panels Market Segmentation
10. Cardiogenomics Testing Panels Market Regional and Country Analysis
11. Asia-Pacific Cardiogenomics Testing Panels Market
12. China Cardiogenomics Testing Panels Market
13. India Cardiogenomics Testing Panels Market
14. Japan Cardiogenomics Testing Panels Market
15. Australia Cardiogenomics Testing Panels Market
16. Indonesia Cardiogenomics Testing Panels Market
17. South Korea Cardiogenomics Testing Panels Market
18. Taiwan Cardiogenomics Testing Panels Market
19. South East Asia Cardiogenomics Testing Panels Market
20. Western Europe Cardiogenomics Testing Panels Market
21. UK Cardiogenomics Testing Panels Market
22. Germany Cardiogenomics Testing Panels Market
23. France Cardiogenomics Testing Panels Market
24. Italy Cardiogenomics Testing Panels Market
25. Spain Cardiogenomics Testing Panels Market
26. Eastern Europe Cardiogenomics Testing Panels Market
27. Russia Cardiogenomics Testing Panels Market
28. North America Cardiogenomics Testing Panels Market
29. USA Cardiogenomics Testing Panels Market
30. Canada Cardiogenomics Testing Panels Market
31. South America Cardiogenomics Testing Panels Market
32. Brazil Cardiogenomics Testing Panels Market
33. Middle East Cardiogenomics Testing Panels Market
34. Africa Cardiogenomics Testing Panels Market
36. Cardiogenomics Testing Panels Market Competitive Landscape and Company Profiles
37. Cardiogenomics Testing Panels Market Other Major and Innovative Companies
40. Cardiogenomics Testing Panels Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Cardiogenomics Testing Panels Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cardiogenomics testing panels market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cardiogenomics testing panels? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cardiogenomics testing panels market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Product Type: Single-Gene Panels; Multi-Gene Panels; Whole Exome Sequencing Panels2) By Technology: Next-Generation Sequencing; PCR-Based Testing; Microarray; Other Technologies
3) By Application: Inherited Cardiovascular Diseases; Arrhythmias; Cardiomyopathies; Congenital Heart Diseases; Other Appications
4) By End User: Hospitals And Clinics; Diagnostic Laboratories; Academic And Research Institutes; Other End Users
Subsegments:
1) By Single-Gene Panels: Ion Channel Gene Panels; Structural Heart Disease Gene Panels; Arrhythmia Gene Panels2) By Multi-Gene Panels: Cardiomyopathy Panels; Arrhythmia Panels; Congenital Heart Disease Panels
3) By Whole Exome Sequencing Panels: Targeted Cardiovascular Exome Panels; Comprehensive Exome Panels; Research-Oriented Exome Panels
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; Laboratory Corporation of America Holdings; Quest Diagnostics Incorporated; Eurofins Scientific SE; Illumina Inc.; Actia Group; Invitae Corporation; Fulgent Genetics Inc.; GeneDx Inc.; Ambry Genetics Corporation; Helix OpCo Inc.; Centogene Gmbh; Blueprint Genetics Inc.; Strand Life Sciences Pvt. Ltd.; Genes2Me Pvt. Ltd.; BioAro Inc.; GENinCode Plc; Igenomix S.L.; Asper Biotech Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cardiogenomics Testing Panels market report include:- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific Inc.
- Laboratory Corporation of America Holdings
- Quest Diagnostics Incorporated
- Eurofins Scientific SE
- Illumina Inc.
- Actia Group
- Invitae Corporation
- Fulgent Genetics Inc.
- GeneDx Inc.
- Ambry Genetics Corporation
- Helix OpCo Inc.
- Centogene Gmbh
- Blueprint Genetics Inc.
- Strand Life Sciences Pvt. Ltd.
- Genes2Me Pvt. Ltd.
- BioAro Inc.
- GENinCode Plc
- Igenomix S.L.
- Asper Biotech Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.75 Billion |
| Forecasted Market Value ( USD | $ 2.78 Billion |
| Compound Annual Growth Rate | 12.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
